Full Text Journal Articles by
Author Rena M Conti

Advertisement

Find full text journal articles






Pharmacy Benefit Manager Reform: Lessons From Ohio.

Trevor J Royce, Sheetal Kircher, Rena M Conti,

JAMA (JAMA)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids.

Kao-Ping Chua, Chad M Brummett, Rena M Conti, Rebecca L Haffajee, Lisa A Prosser, Amy S B Bohnert,

Importance:Most prescription opioid misuse involves opioids prescribed to others-a form of opioid diversion. However, few indicators of diversion risk exist. Because family members can often access patients' opioids, one such indicator may be the frequency with which opioid prescriptions are filled by patients when their family members are engaged in ... Read more >>

JAMA Netw Open (JAMA network open)
[2019, 2(5):e193673]

Cited: 0 times

View full text PDF listing >>



Advertisement

Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014.

Kao-Ping Chua, Rena M Conti,

J Gen Intern Med (Journal of general internal medicine)
[2019, 34(3):338-340]

Cited: 0 times

View full text PDF listing >>



Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?

Rena M Conti, Kevin H Nguyen, Meredith B Rosenthal,

Background:In the United States (U.S.), large price increases for selected generic drugs have elicited public outrage. Recent legislative proposals aim to increase price transparency and identify outlier drug "price spikes." It is unknown how many and what types of products would be highlighted by such efforts. Methods:IQVIA Health Incorporated's National ... Read more >>

J Pharm Policy Pract (Journal of pharmaceutical policy and practice)
[2018, 11:29]

Cited: 0 times

View full text PDF listing >>



Diversity of Participants in the 340B Drug Pricing Program for US Hospitals.

Sayeh Nikpay, Melinda Buntin, Rena M Conti,

JAMA Intern Med (JAMA internal medicine)
[2018, 178(8):1124-1127]

Cited: 0 times

View full text PDF listing >>



Appropriately Framing Child Health Care Spending: A Prerequisite for Value Improvement.

Kao-Ping Chua, Rena M Conti, Gary L Freed,

JAMA (JAMA)
[2018, 319(11):1087-1088]

Cited: 0 times

View full text PDF listing >>



Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/Adenoidectomy.

Kao-Ping Chua, Mark G Shrime, Rena M Conti,

In August 2012, the Food and Drug Administration investigated the safety of codeine use by children after tonsillectomy and/or adenoidectomy, culminating in a black box warning in February 2013. The objective of this study was to evaluate the association between the investigation and opioid prescribing to children undergoing these surgeries.We ... Read more >>

Pediatrics (Pediatrics)
[2017, 140(6):]

Cited: 1 time

View full text PDF listing >>



Biosimilars: Reimbursement Issues in Your Oncology Practice.

Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2017, 13(9_suppl):12s-14s]

Cited: 1 time

View full text PDF listing >>



Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.

Stacie B Dusetzina, Rena M Conti, Nancy L Yu, Peter B Bach,

The increasing cost of prescription drugs is a burden for patients and threatens the financial stability of the US health care system. Rebates are a form of price concession paid by a pharmaceutical manufacturer to the health plan sponsor or the pharmacy benefit manager working on the plan's behalf. Proponents ... Read more >>

JAMA Intern Med (JAMA internal medicine)
[2017, 177(8):1185-1188]

Cited: 7 times

View full text PDF listing >>



Mitigating Financial Toxicity Among US Patients With Cancer.

Jonas A de Souza, Rena M Conti,

JAMA Oncol (JAMA oncology)
[2017, 3(6):765-766]

Cited: 1 time

View full text PDF listing >>



Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014.

Kao-Ping Chua, Rena M Conti,

JAMA Intern Med (JAMA internal medicine)
[2017, 177(5):736-739]

Cited: 2 times

View full text PDF listing >>



Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA.

Rena M Conti, David K Jones,

The ACA entails a number of provisions that are profoundly changing the way the states ensure access to medical care, including the expansion of Medicaid and the maintenance of health insurance exchanges. Here, we argue that while federal policy is the originating force of whether these provisions are adopted, individual ... Read more >>

J Health Polit Policy Law (Journal of health politics, policy and law)
[2017, 42(2):377-385]

Cited: 0 times

View full text PDF listing >>



Use of Low-Value Pediatric Services Among the Commercially Insured.

Kao-Ping Chua, Aaron L Schwartz, Anna Volerman, Rena M Conti, Elbert S Huang,

BACKGROUND:Claims-based measures of "low-value" pediatric services could facilitate the implementation of interventions to reduce the provision of potentially harmful services to children. However, few such measures have been developed. METHODS:We developed claims-based measures of 20 services that typically do not improve child health according to evidence-based guidelines (eg, cough and ... Read more >>

Pediatrics (Pediatrics)
[2016, 138(6):]

Cited: 4 times

View full text PDF listing >>



21st century pharmacovigilance: efforts, roles, and responsibilities.

Peter J Pitts, Hervé Le Louet, Yola Moride, Rena M Conti,

In an era when the number of expedited and conditional review pathways for newly available brand-name drugs and biosimilar medicines to treat serious and life-threatening diseases is increasing, defining pharmacovigilance has never been more crucial. 21st century pharmacovigilance is not merely about uncovering, reporting, and addressing adverse events associated with ... Read more >>

Lancet Oncol. (The Lancet. Oncology)
[2016, 17(11):e486-e492]

Cited: 9 times

View full text PDF listing >>



Pharmaceuticals and Public Health.

Rena M Conti, Rebekah E Gee, Joshua M Sharfstein,

JAMA (JAMA)
[2016, 316(20):2083-2084]

Cited: 1 time

View full text PDF listing >>



A Pathway Through the Bundle Jungle.

Blase Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2016, 12(6):504-509]

Cited: 10 times

View full text PDF listing >>



Overspending driven by oversized single dose vials of cancer drugs.

Peter B Bach, Rena M Conti, Raymond J Muller, Geoffrey C Schnorr, Leonard B Saltz,

BMJ (BMJ (Clinical research ed.))
[2016, 352:i788]

Cited: 25 times

View full text PDF listing >>



Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

William V Padula, Richard A Larson, Stacie B Dusetzina, Jane F Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C Müller, Dietger Niederwieser, Susanne Saussele, Charles A Schiffer, Richard T Silver, Bengt Simonsson, Rena M Conti,

We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib's price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in ... Read more >>

J. Natl. Cancer Inst. (Journal of the National Cancer Institute)
[2016, 108(7):]

Cited: 19 times

View full text PDF listing >>



Pharmaceutical Policy Reform--Balancing Affordability with Incentives for Innovation.

Rena M Conti, Meredith B Rosenthal,

N. Engl. J. Med. (The New England journal of medicine)
[2016, 374(8):703-706]

Cited: 6 times

View full text PDF listing >>



National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions.

Adam B Weiner, Rena M Conti, Scott E Eggener,

PURPOSE:The recent Great Recession from December 2007 to June 2009 presents a unique opportunity to examine whether the incidence of nonpalpable prostate cancer decreases while conservative management for nonpalpable prostate cancer increases during periods of national economic hardship. MATERIALS AND METHODS:We derived rates of national monthly diagnosis and conservative management ... Read more >>

J. Urol. (The Journal of urology)
[2016, 195(5):1383-1389]

Cited: 3 times

View full text PDF listing >>



How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.

Stacie B Dusetzina, Shellie Ellis, Rachel A Freedman, Rena M Conti, Aaron N Winn, James D Chambers, G Caleb Alexander, Haiden A Huskamp, Nancy L Keating,

In February 2008, the US Food and Drug Administration (FDA) granted accelerated approval for bevacizumab for metastatic breast cancer. After public hearings in July 2010, and June 2011, the FDA revoked this approved indication in November 2011, on the basis of additional evidence regarding its risk/benefit profile. The Centers for ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2015, 11(4):313-318]

Cited: 1 time

View full text PDF listing >>



Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.

Rena M Conti, William V Padula, Richard A Larson,

Imatinib is an oral tyrosine kinase inhibitor and considered to be the most successful targeted anti-cancer agent yet developed given its substantial efficacy in treating chronic myeloid leukemia (CML) and other malignant diseases. In the USA and the European Union (EU), Novartis' composition of matter patent on imatinib will expire ... Read more >>

Ann. Hematol. (Annals of hematology)
[2015, 94 Suppl 2:S249-57]

Cited: 14 times

View full text PDF listing >>



Reply to M. Thompson et Al.

Blase Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2015, 11(3):263-264]

Cited: 0 times

View full text PDF listing >>



Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.

Blase Polite, Rena M Conti, Jeffery C Ward,

Treating patients with cancer with infused or injected oncolytics is a core component of outpatient oncology practice. Currently, practices purchase drugs and then bill insurers, colloquially called "buy and bill." Reimbursement for these drugs is the largest source of gross revenue for oncology practices, and as the prices of cancer ... Read more >>

Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting)
[2015, :e75-80]

Cited: 1 time

View full text PDF listing >>



Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change.

Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2015, 11(1):e95-7]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
2.0916 s